Technological advancements of immunoassay products and their massive adoptions, The surging incidence of chronic and infectious diseases are the major factors driving the growth of the market.
According to research report Immunoassay Market is projected to reach $39.0 billion by 2026, at a CAGR of 6.6% during the forecast period.
Based on the product, the immunoassay market is segmented into reagents & kits and analyzers. The reagents & kits segment accounted the largest share of the market. This segment is also expected to register the highest CAGR during the period. The large share of this segment is attributed to their repetitive purchase and massive consumption for various diagnostic purposes.
Based on technology, the market is segmented into ELISA, western blotting, rapid tests, radioimmunoassays, ELISPOT and other technologies. ELISA accounted for the largest share of the market in 2020. The large share of this segment can be attributed the infectious diseases The massive consumption of ELISA in the diagnosis of cancer, and other chronic complications.
The immunoassay market is segmented into four major regions, namely, North America, Europe, Asia Pacific, Latin America and the Middle East & Africa. North America was the largest regional market for market in 2020. The large share of the North American market can be attributed to the increasing per capita healthcare expenditure and technologically advanced healthcare infrastructure which makes the regional market well established.
The global immunoassay market is consolidated. The prominent players operating in this market include Thermo Fisher Scientific (US), Danaher (US), Abbott Laboratories (US) and Roche (Switzerland).
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=436